Physician profile
Gavin Roach
NPI 1669634218
$12,984.52
in general payments reported to CMS, 2019-2025
13 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,798 · 2020: $5,184 · 2021: $5,617 · 2022: $151 · 2023: $125 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $233.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $8,307.50 | 2020-2021 | |
| Genentech, INC. | $2,200.00 | 2021 | |
| Daiichi Sankyo INC. | $1,262.23 | 2019 | |
| Spark Therapeutics, INC. | $396.50 | 2019-2023 | |
| Genentech USA, INC. | $190.66 | 2021-2025 | Hemlibra |
| Alexion Pharmaceuticals, INC. | $150.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $115.02 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $99.57 | 2022 | |
| Novo Nordisk INC | $96.81 | 2020 | |
| Grifols Shared Services North America, INC. | $88.60 | 2019 | |
| Shire North American Group INC | $40.14 | 2019 | |
| Amgen INC. | $37.49 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gavin Roach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.